Advagraf/Prograf Conversion Trial

Inclusion Criteria: * Renal transplant or Renal Pancreas patients who are \> 12 months post transplant * Stable allograft function defined as eGFR \> 30-60ml/min * Renal patients who have a stable tacrolimus trough level of 5-8ng/ml in prior 3 months; Renal pancreas patients who have a stable tacrolimus trough level of 3-10 mg/ml in prior 3 months * Receiving concomitant therapy with mycophenolate mofetil in a dose of 500-1000mg bid or equivalent Exclusion Criteria: * Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study. * History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin. * Treated rejection within 3 months of randomization. * Increased serum creatinine \> 20% within 3 months of randomization. * Subject is pregnant or breastfeeding * Subject has significant co-morbid disease (eg. Malignancy or uncontrolled infection) or disability (e.g. cognitive deficit) which prevents understanding of, or adherence to, the protocol